Repeated administration with δ9- tetrahydrocannabinol regulates µ-opioid receptor density in the rat brain

Abstract

Several studies have demonstrated reciprocal, as well as synergistic interactions between cannabinoid and opioid systems. The aim of this study was to explore the time-related effects of repeated administration of δ⁹-tetrahydrocannabinol on µ-opioid receptor autoradiography in various brain regions of the rat. To this aim, the effects of δ⁹-tetrahydrocannabinol (δ⁹-THC, 5 mg/kg/day; i.p.) were examined after 1, 3, 7 and 14 days of repeated administration on regions containing µ-opioid receptors: (i) forebrain [caudate-putamen, nucleus accumbens (core and shell) and piriform cortex]; (ii) amygdala (medial pars and cortical posteromedial pars), hypothalamus (ventromedial and dorsomedial nuclei, zona incerta), hippocampal regions (CA1, CA2, CA3, dentate girus), hindbrain (substantia nigra and ventral tegmental area); and (iii) thalamus, including 12 thalamic nuclei. In most of these regions, repeated cannabinoid administration increases µ-opioid receptor density; however, the onset, degree of magnitude reached and time-related effects produced by administration with δ⁹-tetrahydrocannabinol are dependent upon the brain region examined. It appears that the major increase in µ-opioid receptor density occurs 1 and 3 days after δ⁹-THC administration. In some regions, this increase is maintained and, for most of the brain areas examined, this effect is no longer significant by 14 days of administration, suggesting tolerance to cannabinoid treatment. Taken together, the results of this study suggest that cannabinoids produce a time-related differential responsiveness in µ-opioid receptor density in several brain areas that may be relevant to an understanding of the alterations associated with cannabinoid exposure.

Get full access to this article

View all access options for this article.

References

Corchero J, Romero J, Fernandez-Ruiz J J, Ramos J A, Fuentes J A, Manzanares J (1999) Time dependent differences of repeated administration with D9-tetrahydrocannabinol in proenkephalin and cannabinoid receptor gene expression and G-protein activation by µ-opioid and cannabinoid receptors in the caudate-putamen . Mol Brain Res 67: 148–157

Fan G H, Wang L Z, Qiu H C, Ma L, Pei G (1999) Inhibition of calcium/calmodulin-dependent protein kinase II in rat hippocampus attenuates morphine tolerance and dependence . Mol Pharmacol 56: 39–45

Fride E (2002) Endocannabinoids in the central nervous system. An overview . Prostaglandins Leukot Essent Fatty Acids 66: 221–233

Hine B, Torrelio M, Gershon S (1975) Interactions between cannabidiol and 9-THC during abstinence in morphine-dependent rats . Life Sci 17: 851–857

Kaymakcalan S, Ayhan I H, Tulunay F C (1977). Naloxone-induced or postwithdrawal abstinence signs in δ9-tetrahydrocannabinol-tolerant rats . Psychopharmacology 55: 243–249

Lu L, Zeng S, Liu D, Ceng X (2000) Inhibition of the amygdala and hippocampal calcium/calmodulin-dependent protein kinase II attenuates the dependence and relapse to morphine differently in rats . Neurosci Lett 291: 191–195

Mansour A, Khachaturian H, Lewis M E, Akil H, Watson S J (1987) Autoradiographic differentiation of mu, delta, and kappa opioid receptors in the rat forebrain and midbrain . J Neurosci 7: 2445–2464

Manzanares J, Corchero J, Romero J, Fernández-Ruiz J J, Ramos J A, Fuentes J A (1999) Pharmacological and biochemical interactions between opioids and cannabinoids . Trends Pharmacol Sci 20: 287–294

Martellotta M C, Cossu G, Fattore L, Gessa G L, Fratta W (1998) Self-administration of the cannabinoid receptor agonist WIN 55,212-2 in drug-naive mice . Neuroscience 85: 327–330

10.

Martin W J, Coffin P O, Attias E, Balinsky M, Tsou K, Walker J M (1999) Anatomical basis for cannabinoid-induced antinociception as revealed by intracerebral microinjections Brain Res 822: 237–242

11.

Meng I D, Manning B H, Martin W J, Fields H L (1998) An analgesia circuit activated by cannabinoids . Nature 395: 381–383

12.

Navarro M, Carrera M R, Fratta W, Valverde O, Cossu G, Fattore L, Chowen J A, Gomez R, del Arco I, Villanua M A, Maldonado R, Koob G F, de Fonseca F R (2001) Functional interaction between opioid and cannabinoid receptors in drug self-administration . J Neurosci 21: 5344–5350

13.

Paxinos G, Watson C (1986) The rat brain in stereotaxic coordinates. Academic Press, London

14.

Rodriguez J J, Mackie K, Pickel V M (2001) Ultrastructural localization of the CB1 cannabinoid receptor in µ-opioid receptor patches of the rat caudate putamen nucleus . J Neurosci 21: 823–833

15.

Salio C, Fischer J, Franzoni M F, Mackie K, Kaneko T, Conrath M (2001) CB1-cannabinoid and µ-opioid receptor co-localization on postsynaptic target in the rat dorsal horn . Neuroreport 12: 3689–3692

16.

Vela G, Ruiz-Gayo M, Fuentes J A (1995a) Anandamide decreases naloxoneprecipitated withdrawal signs in mice chronically treated with morphine . Neuropharmacology 34: 665–668

17.

Vela G, Fuentes J A, Bonnin A, Fernandez-Ruiz J, Ruiz-Gayo M (1995b) Perinatal exposure to δ9-tetrahydrocannabinol (δ9-THC) leads to changes in opioid-related behavioural patterns in rats . Brain Res 680: 142–147

18.

Walker J M, Huang S M, Strangman N M, Tsou K, Sanudo-Pena M C (1999a) Pain modulation by release of the endogenous cannabinoid anandamide . Proc Natl Acad Sci USA 96: 12198–12203

19.

Walker J M, Hohmann AG, Martin WJ, Strangman N M, Huang S M, Tsou K (1999b) The neurobiology of cannabinoid analgesia . Life Sci 65: 665–673